Objectives: The purpose of this study was to investigate the feasibility of hematoma evacuation (HE) with decompressive craniectomy (DC) and to evaluate whether HE with DC is associated with improvement of clinical outcomes in patients with parenchymal hematoma type 2 (PH2) after middle cerebral artery (MCA) infarction.

Methods: Between March 2007 and August 2020, 73 patients with PH2 after MCA infarction underwent DC. The HE group (n = 28) consisted of subjects who underwent HE with DC and the non-HE group (n = 45) consisted of subjects who underwent only DC without HE. The clinical outcomes were analyzed and compared between groups.

Results: Significant differences in clinical outcomes were not observed between the groups at discharge (P = 0.648) and 12-month follow-up (P = 0.346). Mortality rate within 12 months was not significantly different between the groups (log-rank, P = 0.685). There were 12 reoperations in the HE group (42.9%) and three reoperations in the non-HE group (6.7%; P = 0.037). Logistic regression analysis showed the initial National Institutes of Health Stroke Scale score (OR, 2.320; 95% CI, 1.128-5.965; P = 0.046) and the infarction volume (OR, 1.876; 95% CI, 1.935-11.892; P = 0.041) were independently associated with mortality (modified Rankin Scale, 6) within the 12 months.

Conclusions: In patients with PH2 of hemorrhagic transformation after MCA infarction, HE with DC does not change the clinical outcomes or mortality but might increase the reoperation risk.

Download full-text PDF

Source
http://dx.doi.org/10.1080/01616412.2022.2066784DOI Listing

Publication Analysis

Top Keywords

clinical outcomes
20
hematoma evacuation
8
evacuation decompressive
8
decompressive craniectomy
8
outcomes patients
8
patients parenchymal
8
parenchymal hematoma
8
hematoma type
8
hemorrhagic transformation
8
middle cerebral
8

Similar Publications

Background: Tissue-based genomic classifiers (GCs) have been developed to improve prostate cancer (PCa) risk assessment and treatment recommendations.

Purpose: To summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris GCs on risk stratification and patient-clinician decisions on treatment choice among patients with localized PCa considering first-line treatment.

Data Sources: MEDLINE, EMBASE, and Web of Science published from January 2010 to August 2024.

View Article and Find Full Text PDF

Background: Telehealth interventions can effectively support caregivers of people with dementia by providing care and improving their health outcomes. However, to successfully translate research into clinical practice, the content and details of the interventions must be sufficiently reported in published papers.

Objective: This study aims to evaluate the completeness of a telehealth intervention reporting in randomized controlled trials (RCTs) conducted for caregivers of people with dementia.

View Article and Find Full Text PDF

Background: Cognitive deterioration is common in multiple sclerosis (MS) and requires regular follow-up. Currently, cognitive status is measured in clinical practice using paper-and-pencil tests, which are both time-consuming and costly. Remote monitoring of cognitive status could offer a solution because previous studies on telemedicine tools have proved its feasibility and acceptance among people with MS.

View Article and Find Full Text PDF

Efficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia: A Randomized Controlled Trial.

J Clin Psychiatry

January 2025

Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, and Department of Psychiatry, New York University School of Medicine, New York, New York.

There are few established treatments for negative symptoms in schizophrenia, which persist in many patients after positive symptoms are reduced. Oxidative stress, inflammation, and epigenetic modifications involving histone deacetylase (HDAC) have been implicated in the pathophysiology of schizophrenia. Sulforaphane has antioxidant properties and is an HDAC inhibitor.

View Article and Find Full Text PDF

To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!